Company news

Moderna, Inc. news in 2023

Moderna, Inc.'s news releases, calls and decks from 2023, newest first.

View company

BenevolentAI Strengthens its Board of Directors with the Appointment of Digital Innovation Expert Marcello Damiani

March 21, 2023

Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting

March 13, 2023

Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023

March 9, 2023

Moderna to Present at Cowen's 43rd Annual Health Care Conference

February 27, 2023

Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates

February 22, 2023

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk...

February 21, 2023

Moderna And Life Edit Therapeutics Enter Strategic Collaboration to Accelerate the Development of Novel In Vivo Gene Editing Therapies

February 21, 2023

Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Vaccine in Children & Adolescents (6-17 Years)

February 16, 2023

Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate

February 15, 2023

Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023

February 1, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

January 29, 2023

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

January 16, 2023

Moderna Announces Advances Across mRNA Pipeline and Provides Business Update

January 8, 2023

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 4, 2023

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

January 4, 2023

Moderna to Acquire OriCiro Genomics

January 3, 2023

Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference

January 2, 2023

← Newer news releases

Calls in 2023

Decks in 2023